Dr. Lapuerta is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5 Seminole Rd
Skillman, NJ 08558Phone+1 609-216-3513
Education & Training
Harvard Medical SchoolClass of 1989
Certifications & Licensure
CA State Medical License 1992 - Present
NJ State Medical License 1996 - 2025
NC State Medical License 1989 - 1991
Clinical Trials
- Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1) Start of enrollment: 2007 Dec 01
- Pharmacodynamics of CGT 2168 Compared With Plavix® Start of enrollment: 2007 Nov 01
- Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Start of enrollment: 2010 Jun 15
Publications & Presentations
PubMed
- 6 citationsInsights into patients' experience with type 1 diabetes: Exit interviews from phase III studies of sotagliflozinClaire Ervin, Vijay N. Joish, Emily Evans, Dana B. DiBenedetti, Matthew Reaney
Clinical Therapeutics. 2019-10-03 - 12 citationsCost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogs.Vijay N. Joish, F. Frech, Pablo Lapuerta
Journal of Medical Economics. 2018-02-01 - 7 citationsBudgetary Impact of Telotristat Ethyl, a Novel Treatment for Patients with Carcinoid Syndrome Diarrhea: A US Health Plan PerspectiveVijay N. Joish, Feride Frech, Pablo Lapuerta
Clinical Therapeutics. 2017-12-01
Journal Articles
- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart FailureDeepak L Bhatt, Darren K Mcguire, Jeffrey M Testani, Pablo Lapuerta, Bertram Pitt, The New England Journal of Medicine
Press Mentions
Lexicon Pharmaceuticals Announces Positive 52-Week Results from Sotagliflozin inTandem1 Study Presented at ADA 2018 and Published in Diabetes CareJune 25th, 2018- Lexicon Pharmaceuticals Announces Positive 52-Week Results from Sotagliflozin inTandem2 Study Presented at ADA 2018 and Published in Diabetes CareJune 23rd, 2018
Sotagliflozin (Zynquista): A Novel SGLT MedicationJune 16th, 2018- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
